EMV Capital Plc (AIMEMVC) announced its final results for the year ended 31 December 2025, highlighting growth in assets under management (AUM) to ยฃ112.5 million, a 14% increase from 2024. The company reported a 17% rise in group revenue to ยฃ2.9 million, driven by higher corporate finance fees, increased fundraising activity, and higher recurring fund management fees. Despite macroeconomic challenges, EMVC demonstrated resilience, with a narrowed group loss of ยฃ0.6 million, an 83% improvement from the previous year. The company continued to support its portfolio through syndicated fundraisings, totalling ยฃ12.0 million across 14 portfolio companies, and advanced its Venture Build programme, achieving a 12.4x multiple on investments. EMVC also established a new portfolio company, AMR Bio Limited, to address the global threat of antimicrobial resistance. The company strengthened its leadership with key appointments and invested in digital infrastructure and AI strategies to enhance operational efficiency. Post-period highlights include significant regulatory advancements for AMR Bios XF-73 and the appointment of a leadership team with extensive expertise in antimicrobial development. EMVC remains cautiously optimistic about its position across sectors benefiting from long-term structural growth trends.